<p><em><strong>休會 2025 年股東年會</strong></em></p>
<p><em><strong>敦促尚未投票的股東儘快投票</strong></em></p>
<p>Xenetic Biosciences, Inc.（NASDAQ:XBIO）（&#34;Xenetic&#34;或&#34;公司&#34;）是一家專注於推進創新免疫腫瘤技術以應對難治性癌症的生物製藥公司，今天宣佈其 2025 年股東年會（&#34;年會&#34;）已召開並因缺乏所需法定人數而休會，未進行任何業務。</p>
<p>召開年會需要法定人數。在年會上，出席的可投票股份少於已發行股份的多數，無論是親自出席還是通過代理。因此，年會沒有法定人數，決定休會以便為公司董事會徵集更多代理投票提供額外時間。年會將於 2026 年 1 月 8 日星期四東部時間上午 10:00 重新召開，並將繼續以虛擬形式舉行。</p>
<p>已經提交代理或投票的股東無需再次投票，因為之前提交的代理和投票在重新召開的年會上仍然有效，除非被正式撤回。確定有資格在重新召開的年會上投票的股東的記錄日期仍為 2025 年 10 月 15 日。</p>
<p><strong>截至 2025 年 10 月 15 日記錄日期的股東，尚未投票的，鼓勵在線投票，網址為</strong> <strong>www.proxyvote.com</strong> <strong>或撥打電話 1-800-690-6903。請在 2026 年 1 月 7 日東部時間晚上 11:59 之前投票。</strong></p>
<p>如果您在經紀公司、銀行、交易商或其他類似組織的賬户中持有公司的普通股，您可能會面臨更早的投票截止日期，您應仔細查看持有這些股份的組織發送的任何材料，以瞭解如何投票，以確保您的投票被計算在內。</p>
<p>公司的年會正式代理聲明副本可在 www.proxyvote.com 和公司網站 www.xeneticbio.com 上供股東查閲。</p>
<p>截至 2025 年 10 月 15 日年會營業結束時的 Xenetic 股東或其法定代理人，可以通過訪問 http://www.virtualshareholdermeeting.com/XBIO2025 參加重新召開的年會。</p>
<p><strong>股東提問</strong></p>
<p>如果您有任何問題或需要投票的幫助，請致電 Okapi Partners LLC，電話 877-629-6355。</p>
<p><strong>重要信息</strong></p>
<p>本新聞稿可能被視為關於將於 2026 年 1 月 8 日星期四重新召開的年會的徵集材料。與年會相關，公司於 2025 年 10 月 31 日向證券交易委員會（&#34;SEC&#34;）提交了正式代理聲明。在做出任何投票決定之前，公司敦促股東閲讀代理聲明及任何其他與 SEC 提交的相關文件，因為這些文件包含有關年會的重要信息。正式代理聲明已於 2025 年 10 月 31 日左右發送或提供給有權在年會上投票的股東。對股東在年會上投票的提案沒有進行任何更改。公司向 SEC 提交的正式代理聲明及任何其他材料可在 SEC 網站 www.sec.gov 或公司網站 www.xeneticbio.com 免費獲取。</p>
<p><strong>關於 Xenetic Biosciences</strong></p>
<p>Xenetic Biosciences, Inc.是一家專注於推進創新免疫腫瘤技術以應對難治性癌症的生物製藥公司。公司的專有 DNase 技術旨在通過靶向中性粒細胞外陷阱（NETs）來改善現有治療的效果，包括免疫療法，這些 NETs 與癌症進展有關。Xenetic 目前專注於將其系統性 DNase 項目推進到臨牀，作為胰腺癌和局部晚期或轉移性實體瘤的輔助治療。</p>
<p>欲瞭解更多信息，請訪問公司網站 www.xeneticbio.com，並在 X、LinkedIn 和 Facebook 上與我們聯繫。</p>
<p><strong>前瞻性聲明</strong></p>
<p>本新聞稿包含前瞻性聲明，我們意圖使其符合 1995 年《私人證券訴訟改革法》的安全港條款。本新聞稿中除歷史事實陳述外的所有聲明可能構成聯邦證券法意義上的前瞻性聲明。這些聲明可以通過諸如 “預計”、“計劃”、“項目”、“將”、“可能”、“預期”、“相信”、“應該”、“意圖”、“估計”、“保持”、“關注”、“信心”、“潛力”、“持續”、“保證” 等詞語以及其他類似含義的詞語來識別，包括但不限於，所有關於我們專注於推進創新免疫腫瘤技術以應對難治性癌症的聲明，DNase 平台通過靶向與癌症進展相關的中性粒細胞外陷阱（NETs）來改善現有治療（包括免疫療法）的結果，以及我們專注於將系統性 DNase 項目推進到臨牀作為胰腺癌和局部晚期或轉移性實體瘤的輔助治療的聲明。此處包含的任何前瞻性聲明均基於當前預期，並受到多種風險和不確定性的影響。許多因素可能導致我們的實際活動、表現、成就或結果與前瞻性聲明中預期的活動和結果存在重大差異。可能導致實際活動、表現、成就或結果與此類計劃、估計或預期存在重大差異的重要因素包括但不限於：（1）由於我們的製造和合作協議而產生的意外成本、費用或支出；（2）由於 DNase 平台的許可而產生的意外成本、費用或支出；（3）在 DNase 平台許可後，公司預期財務表現的不確定性；（4）未能實現 DNase 或 PolyXen 技術的預期潛力；（5）公司獲得資金和實施其商業戰略的能力；（6）董事會及其特別獨立委員會進行的戰略審查過程的結果和時機的不確定性，包括董事會在評估過程中可能決定不採取戰略替代方案的可能性，公司因市場、監管和其他因素而無法完成審查所提出的任何戰略替代方案的可能性，審查過程對我們業務造成的潛在干擾，以及評估過程的公告、暫停或完成及其結果對公司股價的潛在不利影響，以及與戰略交易完成對公司當前業務運營、預期商業戰略和產品開發計劃的潛在影響相關的風險和不確定性；以及（7）其他風險因素，詳見公司不時向 SEC 提交的報告，包括其 10-K 表格的年度報告、10-Q 表格的定期季度報告、8-K 表格的當前報告及其他向 SEC 提交的文件。上述重要因素的清單並不排他。此外，前瞻性聲明也可能受到一般市場因素、一般經濟和商業條件的負面影響，包括公共健康問題的潛在不利影響，以及地緣政治事件（如烏克蘭和中東的衝突）對經濟活動、競爭產品開發、產品可用性、聯邦和州法規及立法、新產品候選和適應症的監管流程、可能出現的製造問題、專利狀況、訴訟和股東行動主義等因素的影響。本文中包含的前瞻性聲明僅在聲明作出之日有效，公司不承擔更新前瞻性聲明的任何義務，法律要求的除外。</p>
<p><strong>聯繫方式：</strong></p>
<p>JTC Team, LLC</p>
<p>Jenene Thomas</p>
<p>(908) 824-0775</p>
<p>xbio@jtcir.com</p>
<p><strong>來源：</strong> Xenetic Biosciences, Inc.</p>
<p>查看原始新聞稿，請訪問 ACCESS Newswire</p>
<p><img src="https://imageproxy.pbkrs.com/https://app.accessnewswire.com/img.ashx/query-aWQ9MTExNjkxNg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://app.accessnewswire.com/img.ashx/query-aWQ9MTExNjkxNg"/></p>

XBIO

<p>Xenetic Biosciences, Inc. 宣佈由於缺乏法定人數，2025 年股東年會將延期。會議將於 2026 年 1 月 8 日以虛擬形式重新召開。尚未投票的股東被敦促在 2026 年 1 月 7 日之前進行投票。已經提交的代理和投票仍然有效，除非被撤回。投票資格的記錄日期為 2025 年 10 月 15 日。公司強調閲讀已向 SEC 提交的代理聲明以獲取重要信息</p>

<p><em><strong>Adjourns 2025 Annual Meeting of Stockholders</strong></em></p>
<div class="lb-trans"><p><em><strong>休會 2025 年股東年會</strong></em></p>
</div><p><em><strong>Urges Stockholders Who Have Not Voted To Get Votes In</strong></em></p>
<div class="lb-trans"><p><em><strong>敦促尚未投票的股東儘快投票</strong></em></p>
</div><p>Xenetic Biosciences, Inc. (NASDAQ:XBIO) (&#34;Xenetic&#34; or the &#34;Company&#34;), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers, today announced that its 2025 Annual Meeting of Stockholders (the &#34;Annual Meeting&#34;) was convened and adjourned without any business conducted due to lack of the required quorum.</p>
<div class="lb-trans"><p>Xenetic Biosciences, Inc.（NASDAQ:XBIO）（&#34;Xenetic&#34;或&#34;公司&#34;）是一家專注於推進創新免疫腫瘤技術以應對難治性癌症的生物製藥公司，今天宣佈其 2025 年股東年會（&#34;年會&#34;）已召開並因缺乏所需法定人數而休會，未進行任何業務。</p>
</div><p>A quorum is necessary to hold the Annual Meeting. There were fewer than a majority of the outstanding shares entitled to vote present, either in person or by proxy, at the Annual Meeting. The Annual Meeting therefore had no quorum and was adjourned to allow additional time to solicit additional proxies on behalf of the Company's board of directors. The Annual Meeting will reconvene at 10:00 a.m. Eastern Time on Thursday, January 8, 2026, and will continue to be held virtually.</p>
<div class="lb-trans"><p>召開年會需要法定人數。在年會上，出席的可投票股份少於已發行股份的多數，無論是親自出席還是通過代理。因此，年會沒有法定人數，決定休會以便為公司董事會徵集更多代理投票提供額外時間。年會將於 2026 年 1 月 8 日星期四東部時間上午 10:00 重新召開，並將繼續以虛擬形式舉行。</p>
</div><p>Stockholders who have already submitted a proxy or voted do not need to vote again, as proxies and votes previously submitted in respect of the Annual Meeting will remain valid at the reconvened Annual Meeting unless properly revoked. The record date for determining stockholders eligible to vote at the reconvened Annual Meeting remains October 15, 2025.</p>
<div class="lb-trans"><p>已經提交代理或投票的股東無需再次投票，因為之前提交的代理和投票在重新召開的年會上仍然有效，除非被正式撤回。確定有資格在重新召開的年會上投票的股東的記錄日期仍為 2025 年 10 月 15 日。</p>
</div><p><strong>Stockholders as of the October 15, 2025 record date who have not yet voted are encouraged to vote online at</strong> <strong>www.proxyvote.com</strong> <strong>or by telephone at 1-800-690-6903. Please vote by 11:59 p.m. Eastern Time on January 7, 2026.</strong></p>
<div class="lb-trans"><p><strong>截至 2025 年 10 月 15 日記錄日期的股東，尚未投票的，鼓勵在線投票，網址為</strong> <strong>www.proxyvote.com</strong> <strong>或撥打電話 1-800-690-6903。請在 2026 年 1 月 7 日東部時間晚上 11:59 之前投票。</strong></p>
</div><p>If you hold your shares of the Company's common stock in an account at a brokerage firm, bank, dealer or other similar organization, you may be subject to an earlier voting deadline and you should carefully review any materials received from the organization holding those shares regarding how to vote to ensure your vote is counted.</p>
<div class="lb-trans"><p>如果您在經紀公司、銀行、交易商或其他類似組織的賬户中持有公司的普通股，您可能會面臨更早的投票截止日期，您應仔細查看持有這些股份的組織發送的任何材料，以瞭解如何投票，以確保您的投票被計算在內。</p>
</div><p>A copy of the Company's definitive proxy statement for the Annual Meeting is available to stockholders on www.proxyvote.com and on the Company's website at www.xeneticbio.com.</p>
<div class="lb-trans"><p>公司的年會正式代理聲明副本可在 www.proxyvote.com 和公司網站 www.xeneticbio.com 上供股東查閲。</p>
</div><p>Xenetic stockholders as of the close of business on the October 15, 2025 record date for the Annual Meeting, or their legal proxy holders, will be able to attend the reconvened Annual Meeting by visiting http://www.virtualshareholdermeeting.com/XBIO2025.</p>
<div class="lb-trans"><p>截至 2025 年 10 月 15 日年會營業結束時的 Xenetic 股東或其法定代理人，可以通過訪問 http://www.virtualshareholdermeeting.com/XBIO2025 參加重新召開的年會。</p>
</div><p><strong>Stockholder Questions</strong></p>
<div class="lb-trans"><p><strong>股東提問</strong></p>
</div><p>If you have any questions or require any assistance in voting your shares, please call Okapi Partners LLC at 877-629-6355.</p>
<div class="lb-trans"><p>如果您有任何問題或需要投票的幫助，請致電 Okapi Partners LLC，電話 877-629-6355。</p>
</div><p><strong>Important Information</strong></p>
<div class="lb-trans"><p><strong>重要信息</strong></p>
</div><p>This press release may be deemed to be solicitation material in respect of the Annual Meeting to be reconvened and held on Thursday, January 8, 2026. In connection with the Annual Meeting, the Company filed a definitive proxy statement with the Securities and Exchange Commission (&#34;SEC&#34;) on October 31, 2025. BEFORE MAKING ANY VOTING DECISION, THE COMPANY URGES ITS STOCKHOLDERS TO READ THE PROXY STATEMENT AND ANY OTHER RELEVANT DOCUMENTS FILED WITH THE SEC BECAUSE THEY CONTAIN IMPORTANT INFORMATION ABOUT THE ANNUAL MEETING. The definitive proxy statement was sent or made available to stockholders entitled to vote at the Annual Meeting on or about October 31, 2025. No changes have been made to the proposals to be voted on by stockholders at the Annual Meeting. A copy of the definitive proxy statement and any other materials filed by the company with the SEC can be obtained free of charge at the SEC's website at www.sec.gov or the company's website at www.xeneticbio.com.</p>
<div class="lb-trans"><p>本新聞稿可能被視為關於將於 2026 年 1 月 8 日星期四重新召開的年會的徵集材料。與年會相關，公司於 2025 年 10 月 31 日向證券交易委員會（&#34;SEC&#34;）提交了正式代理聲明。在做出任何投票決定之前，公司敦促股東閲讀代理聲明及任何其他與 SEC 提交的相關文件，因為這些文件包含有關年會的重要信息。正式代理聲明已於 2025 年 10 月 31 日左右發送或提供給有權在年會上投票的股東。對股東在年會上投票的提案沒有進行任何更改。公司向 SEC 提交的正式代理聲明及任何其他材料可在 SEC 網站 www.sec.gov 或公司網站 www.xeneticbio.com 免費獲取。</p>
</div><p><strong>About Xenetic Biosciences</strong></p>
<div class="lb-trans"><p><strong>關於 Xenetic Biosciences</strong></p>
</div><p>Xenetic Biosciences, Inc. is a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers. The Company's proprietary DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in cancer progression. Xenetic is currently focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and locally advanced or metastatic solid tumors.</p>
<div class="lb-trans"><p>Xenetic Biosciences, Inc.是一家專注於推進創新免疫腫瘤技術以應對難治性癌症的生物製藥公司。公司的專有 DNase 技術旨在通過靶向中性粒細胞外陷阱（NETs）來改善現有治療的效果，包括免疫療法，這些 NETs 與癌症進展有關。Xenetic 目前專注於將其系統性 DNase 項目推進到臨牀，作為胰腺癌和局部晚期或轉移性實體瘤的輔助治療。</p>
</div><p>For more information, please visit the Company's website at www.xeneticbio.com and connect on X, LinkedIn, and Facebook.</p>
<div class="lb-trans"><p>欲瞭解更多信息，請訪問公司網站 www.xeneticbio.com，並在 X、LinkedIn 和 Facebook 上與我們聯繫。</p>
</div><p><strong>FORWARD-LOOKING STATEMENTS</strong></p>
<div class="lb-trans"><p><strong>前瞻性聲明</strong></p>
</div><p>This press release contains forward-looking statements that we intend to be subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release other than statements of historical facts may constitute forward-looking statements within the meaning of the federal securities laws. These statements can be identified by words such as &#34;expects,&#34; &#34;plans,&#34; &#34;projects,&#34; &#34;will,&#34; &#34;may,&#34; &#34;anticipates,&#34; &#34;believes,&#34; &#34;should,&#34; &#34;intends,&#34; &#34;estimates,&#34; &#34;remain,&#34; &#34;focus&#34;, &#34;confidence in&#34;, &#34;potential&#34;, &#34;continues&#34;, &#34;warrants&#34;, and other words of similar meaning, including, but not limited to, all statements regarding our focus on advancing innovative immuno-oncology technologies addressing difficult to treat cancers, the DNase platform improving outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in cancer progression, and our focus on advancing our systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and locally advanced or metastatic solid tumors. Any forward-looking statements contained herein are based on current expectations and are subject to a number of risks and uncertainties. Many factors could cause our actual activities, performance, achievements, or results to differ materially from the activities and results anticipated in forward-looking statements. Important factors that could cause actual activities, performance, achievements, or results to differ materially from such plans, estimates or expectations include, among others, (1) unexpected costs, charges or expenses resulting from our manufacturing and collaboration agreements; (2) unexpected costs, charges or expenses resulting from the licensing of the DNase platform; (3) uncertainty of the expected financial performance of the Company following the licensing of the DNase platform; (4) failure to realize the anticipated potential of the DNase or PolyXen technologies; (5) the ability of the Company to obtain funding and implement its business strategy; (6) risks and uncertainties as to the outcome and timing of the strategic review process being conducted by the Board and a special independent committee thereof, including the possibility that the Board may decide not to undertake a strategic alternative following the evaluation process, the Company's inability to consummate any proposed strategic alternative resulting from the review due to, among other things, market, regulatory and other factors, the potential for disruption to our business resulting from the review process, and potential adverse effects on the Company's stock price from the announcement, suspension or consummation of the evaluation process and the results thereof, as well as risks and uncertainties related to the potential impacts of consummation of a strategic transaction on the Company's current business operations, anticipated business strategy and product development plans; and (7) other risk factors as detailed from time to time in the Company's reports filed with the SEC, including its annual report on Form 10-K, periodic quarterly reports on Form 10-Q, current reports on Form 8-K and other documents filed with the SEC. The foregoing list of important factors is not exclusive. In addition, forward-looking statements may also be adversely affected by general market factors, general economic and business conditions, including potential adverse effects of public health issues, and geopolitical events, such as the conflicts in Ukraine and in the Middle East, on economic activity, competitive product development, product availability, federal and state regulations and legislation, the regulatory process for new product candidates and indications, manufacturing issues that may arise, patent positions, litigation, and shareholder activism, among other factors. The forward-looking statements contained in this press release speak only as of the date the statements were made, and the Company does not undertake any obligation to update forward-looking statements, except as required by law.</p>
<div class="lb-trans"><p>本新聞稿包含前瞻性聲明，我們意圖使其符合 1995 年《私人證券訴訟改革法》的安全港條款。本新聞稿中除歷史事實陳述外的所有聲明可能構成聯邦證券法意義上的前瞻性聲明。這些聲明可以通過諸如 “預計”、“計劃”、“項目”、“將”、“可能”、“預期”、“相信”、“應該”、“意圖”、“估計”、“保持”、“關注”、“信心”、“潛力”、“持續”、“保證” 等詞語以及其他類似含義的詞語來識別，包括但不限於，所有關於我們專注於推進創新免疫腫瘤技術以應對難治性癌症的聲明，DNase 平台通過靶向與癌症進展相關的中性粒細胞外陷阱（NETs）來改善現有治療（包括免疫療法）的結果，以及我們專注於將系統性 DNase 項目推進到臨牀作為胰腺癌和局部晚期或轉移性實體瘤的輔助治療的聲明。此處包含的任何前瞻性聲明均基於當前預期，並受到多種風險和不確定性的影響。許多因素可能導致我們的實際活動、表現、成就或結果與前瞻性聲明中預期的活動和結果存在重大差異。可能導致實際活動、表現、成就或結果與此類計劃、估計或預期存在重大差異的重要因素包括但不限於：（1）由於我們的製造和合作協議而產生的意外成本、費用或支出；（2）由於 DNase 平台的許可而產生的意外成本、費用或支出；（3）在 DNase 平台許可後，公司預期財務表現的不確定性；（4）未能實現 DNase 或 PolyXen 技術的預期潛力；（5）公司獲得資金和實施其商業戰略的能力；（6）董事會及其特別獨立委員會進行的戰略審查過程的結果和時機的不確定性，包括董事會在評估過程中可能決定不採取戰略替代方案的可能性，公司因市場、監管和其他因素而無法完成審查所提出的任何戰略替代方案的可能性，審查過程對我們業務造成的潛在干擾，以及評估過程的公告、暫停或完成及其結果對公司股價的潛在不利影響，以及與戰略交易完成對公司當前業務運營、預期商業戰略和產品開發計劃的潛在影響相關的風險和不確定性；以及（7）其他風險因素，詳見公司不時向 SEC 提交的報告，包括其 10-K 表格的年度報告、10-Q 表格的定期季度報告、8-K 表格的當前報告及其他向 SEC 提交的文件。上述重要因素的清單並不排他。此外，前瞻性聲明也可能受到一般市場因素、一般經濟和商業條件的負面影響，包括公共健康問題的潛在不利影響，以及地緣政治事件（如烏克蘭和中東的衝突）對經濟活動、競爭產品開發、產品可用性、聯邦和州法規及立法、新產品候選和適應症的監管流程、可能出現的製造問題、專利狀況、訴訟和股東行動主義等因素的影響。本文中包含的前瞻性聲明僅在聲明作出之日有效，公司不承擔更新前瞻性聲明的任何義務，法律要求的除外。</p>
</div><p><strong>Contact:</strong></p>
<div class="lb-trans"><p><strong>聯繫方式：</strong></p>
</div><p>JTC Team, LLC</p>
<div class="lb-trans"><p>JTC Team, LLC</p>
</div><p>Jenene Thomas</p>
<div class="lb-trans"><p>Jenene Thomas</p>
</div><p>(908) 824-0775</p>
<div class="lb-trans"><p>(908) 824-0775</p>
</div><p>xbio@jtcir.com</p>
<div class="lb-trans"><p>xbio@jtcir.com</p>
</div><p><strong>SOURCE:</strong> Xenetic Biosciences, Inc.</p>
<div class="lb-trans"><p><strong>來源：</strong> Xenetic Biosciences, Inc.</p>
</div><p>View the original press release on ACCESS Newswire</p>
<div class="lb-trans"><p>查看原始新聞稿，請訪問 ACCESS Newswire</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://app.accessnewswire.com/img.ashx/query-aWQ9MTExNjkxNg" alt="" original-src="https://app.accessnewswire.com/img.ashx?id=1116916"/></p>

Xenetic Biosciences, Inc. 宣佈推遲 2025 年年度會議 | XBIO 股票新聞